News

This interview with Dr. Bhatia featured a discussion about his views on newer therapies for dermatologic conditions as well as his outlook on the current research landscape.

Our latest cardiology case report from Brady Pregerson, MD, features a man in his mid-60s presenting with chest pains and palpitations. Can you determine the correct diganosis?

In this segment of her interview, Hebert went further in depth about the main points covered in her conference talk regarding new developments in pediatric dermatology.

This interview featured a discussion with Dr. Hebert in which she addressed the biggest takeaways of her conference presentation titled ‘What’s New in Pediatric Dermatology.’

This interview segment featured Dr. Alexis describing his views on the ways in which the dermatology field may be able to better address disparities in care for those with skin of color.

Cases have increased annually; a clinician shares his strategy for remaining aggressive and diligent in prevention and management.

In this interview, Dr. Alexis spoke about the ways in which the dermatology field should address the needs of patients with skin of color.

In this segment, Dr. Del Rosso discussed a conference presentation he gave titled ‘What You Really Need to Know About Rosacea.’

Secukinumab and bimekizumab may reach the market soon for the treatment of HS. What will it provide patients?

The cross-specialty collaboration between dermatologists and these fields has been a daily occurrence, as inflammation-targeting drugs and comorbid patients have brought team closer together.

During the next part of his Q&A interview, Dr. Lebwohl further described new and future research into treating psoriasis.

Since roflumilast cream was approved by the FDA last July, one dermatology physician assistant advocates for its use as a primary medication.

This Q&A interview with Dr. Lebwohl featured a discussion about which therapies may be the best for patients who have psoriasis.

The introduction of the TYK2 inhibitor is the latest advancement toward cross-specialty care with systemic agents.

Ahead of Fall Clinical Dermatology 2023 Conference for PAs & NPs, Glick discusses how the COVID-19 reshaped dermatology roles, and the value of physician assistants and nurse practitioners in the current care team.

Dr. Del Rosso spoke regarding his conference presentation, titled ‘What’s New in the Medicine Chest,’ in which he describes newer therapies in the dermatology field.

An analysis based in Japan suggests ranibizumab biosimilar is dominant to other anti-VEGF treatments in patients with nAMD in both treat-and-extend and PRN regimens.

In recent years, the field of endophenotyping has garnered significant attention in sleep health, signaling a growing recognition of the need to move beyond simplistic measures.

Alopecia areata patients had higher rates of diseases including psoriasis, allergic rhinitis, asthma, and atopic dermatitis, highlighting the burden of comorbidities on patients in the US.

Lemborexant was statistically similar to placebo on both day 1 and day 8 for any group in latency to persistent sleep, but superior in sleep efficiency and wake after sleep onset.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.

The analysis of the XPLORE trial suggested XSB-001 showed biosimilarity to reference ranibizumab as assessed by BCVA improvement at 8 weeks.

Patients participating in the open-label extension trial had a few months for titration, more than 24 months for stable dosing, and a one-week follow up.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

“How can we use these data to harness the power it has to do a better job of predicting clinical outcomes and looking at treatment responsiveness?” Dr. Reena Mehra asks.

Amid mass poor air quality exposure due to ongoing Canadian wildfires, Lungcast reviews air quality index, signs and symptoms of acute and long-term poor air exposure, high-risk patient populations, and the concerning future of particle pollution exposure.